| Primary |
| Drug Use For Unknown Indication |
17.6% |
| Atrial Fibrillation |
11.8% |
| Aortic Valve Replacement |
7.8% |
| Cardiac Failure Chronic |
7.8% |
| Hypertension |
7.8% |
| Thrombosis Prophylaxis |
7.8% |
| Coronary Artery Disease |
5.9% |
| Coronary Arterial Stent Insertion |
3.9% |
| Essential Hypertension |
3.9% |
| Hyperlipidaemia |
3.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.9% |
| Age-related Macular Degeneration |
2.0% |
| Atrial Flutter |
2.0% |
| Dyslipidaemia |
2.0% |
| Fungal Infection |
2.0% |
| Heart Valve Replacement |
2.0% |
| Intertrigo |
2.0% |
| Myocardial Ischaemia |
2.0% |
| Pain |
2.0% |
| Pulmonary Embolism |
2.0% |
|
| International Normalised Ratio Increased |
28.6% |
| Gastrointestinal Haemorrhage |
21.4% |
| Anaemia |
7.1% |
| Cutaneous Lupus Erythematosus |
7.1% |
| Liver Injury |
7.1% |
| Oesophagitis Haemorrhagic |
7.1% |
| Prothrombin Time Prolonged |
7.1% |
| Subdural Haematoma |
7.1% |
| Toxicity To Various Agents |
7.1% |
|
| Secondary |
| Product Used For Unknown Indication |
25.9% |
| Drug Abuse |
23.6% |
| Hypertension |
8.7% |
| Drug Use For Unknown Indication |
8.6% |
| Atrial Fibrillation |
6.6% |
| Coronary Artery Disease |
4.2% |
| Thrombosis Prophylaxis |
3.6% |
| Aortic Valve Replacement |
3.5% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Hyperlipidaemia |
2.3% |
| Atrial Flutter |
1.3% |
| Epilepsy |
1.3% |
| Dermatitis |
1.2% |
| Prophylaxis |
1.1% |
| Grand Mal Convulsion |
1.0% |
| Pruritus |
1.0% |
| Rheumatoid Arthritis |
0.9% |
| Tachycardia Paroxysmal |
0.9% |
| Type 2 Diabetes Mellitus |
0.9% |
| Essential Hypertension |
0.8% |
|
| Cutaneous Lupus Erythematosus |
11.3% |
| Toxic Epidermal Necrolysis |
11.3% |
| Drug Interaction |
10.0% |
| Gastrointestinal Haemorrhage |
10.0% |
| Prothrombin Time Prolonged |
7.5% |
| Gastritis Haemorrhagic |
5.0% |
| Hyperglycaemia |
5.0% |
| Rib Fracture |
5.0% |
| Vomiting |
5.0% |
| Epistaxis |
3.8% |
| International Normalised Ratio Increased |
3.8% |
| Concomitant Disease Progression |
2.5% |
| Fallot's Tetralogy |
2.5% |
| General Physical Health Deterioration |
2.5% |
| Haematuria |
2.5% |
| Haemorrhage |
2.5% |
| Hyperkalaemia |
2.5% |
| Mucosal Haemorrhage |
2.5% |
| Oesophagitis Haemorrhagic |
2.5% |
| Pancreatitis Acute |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.7% |
| Drug Use For Unknown Indication |
16.5% |
| Atrial Fibrillation |
13.7% |
| Hypertension |
11.5% |
| Renal Failure Chronic |
5.8% |
| Rheumatoid Arthritis |
4.9% |
| Pain |
3.5% |
| Prophylaxis |
2.7% |
| Cardiac Failure |
2.6% |
| Coronary Artery Disease |
2.5% |
| Prostate Cancer |
2.2% |
| Hyperparathyroidism Secondary |
2.0% |
| Hyperlipidaemia |
1.8% |
| Diabetes Mellitus |
1.8% |
| Osteoporosis |
1.6% |
| Cardiac Failure Congestive |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Anticoagulant Therapy |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
|
| Hepatic Enzyme Increased |
9.1% |
| Renal Failure Acute |
9.1% |
| Fatigue |
7.0% |
| Pain |
7.0% |
| Sepsis |
6.4% |
| Wrong Technique In Drug Usage Process |
5.9% |
| Dyspnoea |
4.8% |
| Rhabdomyolysis |
4.8% |
| Anal Fissure |
4.3% |
| Pleural Effusion |
4.3% |
| Pyrexia |
4.3% |
| Allergic Granulomatous Angiitis |
3.7% |
| Cardiac Failure |
3.7% |
| Gastritis Erosive |
3.7% |
| Haemorrhoids |
3.7% |
| Multi-organ Failure |
3.7% |
| Oedema Peripheral |
3.7% |
| Palpitations |
3.7% |
| Weight Decreased |
3.7% |
| Hypersensitivity |
3.2% |
|
| Interacting |
| Product Used For Unknown Indication |
46.1% |
| Drug Use For Unknown Indication |
12.2% |
| Atrial Fibrillation |
6.1% |
| Pulmonary Arterial Hypertension |
5.2% |
| Hypertension |
2.6% |
| Ill-defined Disorder |
2.6% |
| Intertrigo |
2.6% |
| Prophylaxis |
2.6% |
| Renal Transplant |
2.6% |
| Acute Myocardial Infarction |
1.7% |
| Breast Cancer |
1.7% |
| Fungal Infection |
1.7% |
| Fungal Skin Infection |
1.7% |
| Hyperlipidaemia |
1.7% |
| Rash |
1.7% |
| Renal Failure Chronic |
1.7% |
| Respiratory Tract Infection |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Anaemia |
0.9% |
| Bladder Disorder |
0.9% |
|
| International Normalised Ratio Increased |
33.3% |
| Drug Interaction |
13.3% |
| Coagulation Test Abnormal |
6.7% |
| Haemorrhage |
6.7% |
| Prothrombin Time Abnormal |
6.7% |
| Gastrointestinal Haemorrhage |
3.3% |
| Haematemesis |
3.3% |
| Haematuria |
3.3% |
| Hyperkalaemia |
3.3% |
| International Normalised Ratio Abnormal |
3.3% |
| International Normalised Ratio Decreased |
3.3% |
| Prothrombin Time Prolonged |
3.3% |
| Respiratory Tract Haemorrhage |
3.3% |
| Urogenital Haemorrhage |
3.3% |
| Visual Acuity Reduced |
3.3% |
|
